A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL
Eyre, T. A., et al. A phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 Inhibitor Vistusertib in Relapsed, Refractory DLBCL. Hematological Oncology 2019; 37:352-359.
- Peer Reviewed Publications